

COLISTIMETHATE- colistimethate injection, powder, lyophilized, for solution XGen Pharmaceuticals DJB, Inc.

Colistimethate for Injection, USP

Rx Only

FOR INTRAMUSCULAR AND INTRAVENOUS USE

FOR INTRAMUSCULAR AND INTRAVENOUS USE


To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection and other antibacterial drugs, Colistimethate for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Colistimethate for Injection USP is a sterile parenteral antibiotic product which, when reconstituted (see **Reconstitution**), is suitable for intramuscular or intravenous administration.

Each vial contains colistimethate sodium or pentasodium colistinmethanesulfonate (150 mg colistin base activity).


Colistimethate sodium is a polypeptide antibiotic with an approximate molecular weight of 1750. The empirical formula is $C_{58}H_{105}N_{16}Na_5O_{28}S_5$ and the structural formula is represented below:



Dbu is 2, 4-diaminobutanoic acid; R is 5-methylheptyl in colistin A and 5-methylhexyl in colistin B

CLINICAL PHARMACOLOGY

Typical serum and urine levels following a single 150 mg dose of Colistimethate for Injection IM or IV in normal adult subjects are shown in Figure 1.



Higher serum levels were obtained at 10 minutes following IV administration. Serum concentration declined with a half-life of 2-3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.

Average urine levels ranged from about 270 mcg/mL at 2 hours to about 15 mcg/mL at 8 hours after intravenous administration and from 200 to about 25 mcg/mL during a similar period following intramuscular administration.

Microbiology

Colistimethate sodium is a surface active agent which penetrates into and disrupts the bacterial cell membrane. It has been shown to have bactericidal activity against most strains of the following microorganisms, both *in vitro* and in clinical infections as described in the **INDICATIONS AND USAGE** section:

Aerobic gram-negative microorganisms: *Enterobacter aerogenes*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas Aeruginosa* and *Acinetobacter baumannii*.

Susceptibility Tests

Colistimethate sodium is no longer listed as an antimicrobial for routine testing and reporting by clinical microbiology laboratories.

INDICATIONS AND USAGE

Colistimethate for Injection is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of *Pseudomonas aeruginosa*. This antibiotic is not indicated for infections due to *Proteus* or *Neisseria*. Colistimethate for Injection has

proven clinically effective in treatment of infections due to the following gram-negative organisms: *Enterobacter aerogenes*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas Aeruginosa*.

Colistimethate for Injection may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection and other antibacterial drugs, Colistimethate for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS

The use of Colistimethate for Injection is contraindicated for patients with a history of sensitivity to the drug or any of its components.

WARNINGS

Maximum daily dose should not exceed 5 mg/kg/day (2.3 mg/lb) with normal renal function.

Transient neurological disturbances may occur. These include circumoral paresthesia or numbness, tingling or formication of the extremities, generalized pruritus, vertigo, dizziness, and slurring of speech. For these reasons, patients should be warned not to drive vehicles or use hazardous machinery while on therapy. Reduction of dosage may alleviate symptoms. Therapy need not be discontinued, but such patients should be observed with particular care.

Nephrotoxicity can occur and is probably a dose-dependent effect of colistimethate sodium. These manifestations of nephrotoxicity are reversible following discontinuation of the antibiotic.

Overdosage can result in renal insufficiency, muscle weakness, and apnea (see **OVERDOSAGE** section). See **PRECAUTIONS , Drug Interactions** subsection for use concomitantly with other antibiotics and curariform drugs.

Respiratory arrest has been reported following intramuscular administration of colistimethate sodium. Impaired renal function increases the possibility of apnea and neuromuscular blockade following administration of colistimethate sodium. Therefore, it is important to follow recommended dosing guidelines. See **DOSAGE AND ADMINISTRATION** section for use in renal impairment.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including colistimethate for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD.

Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

PRECAUTIONS

General

Since Colistimethate for Injection is eliminated mainly by renal excretion, it should be used with caution when the possibility of impaired renal function exists. The decline in renal function with advanced age should be considered.

When actual renal impairment is present, Colistimethate for Injection may be used, but the greatest caution should be exercised and the dosage should be reduced in proportion to the extent of the impairment. Administration of amounts of Colistimethate for Injection in excess of renal excretory capacity will lead to high serum levels and can result in further impairment of renal function, initiating a cycle which, if not recognized, can lead to acute renal insufficiency, renal shutdown, and further concentration of the antibiotic to toxic levels in the body. At this point, interference of nerve transmission at neuromuscular junctions may occur and result in muscle weakness and apnea (see OVERDOSAGE section).

Signs indicating the development of impaired renal function include: diminishing urine output, rising BUN and serum creatinine and decreased creatinine clearance. Therapy with Colistimethate for Injection should be discontinued immediately if signs of impaired renal function occur. However, if it is necessary to reinstate the drug, dosing should be adjusted accordingly after drug plasma levels have fallen (see DOSAGE AND ADMINISTRATION section).

Prescribing Colistimethate for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Drug Interactions

Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction. Based on this reported activity, they should not be given concomitantly with Colistimethate for Injection except with greatest caution.

Curariform muscle relaxants (e.g., tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium, and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Colistimethate for Injection.

Sodium cephalothin may enhance the nephrotoxicity of Colistimethate for Injection. The

concomitant use of sodium cephalothin and Colistimethate for Injection should be avoided.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal carcinogenicity studies and genetic toxicology studies have not been performed with colistimethate sodium. There were no adverse effects on fertility or reproduction in rats at doses of 9.3 mg/kg/day (0.30 times the maximum daily human dose when based on mg/m²).

Pregnancy

Teratogenic Effects

Pregnancy Category C: Colistimethate sodium given intramuscularly during organogenesis to rabbits at 4.15 and 9.3 mg/kg resulted in talipes varus in 2.6% and 2.9% of fetuses, respectively. These doses are 0.25 and 0.55 times the maximum daily human dose based on mg/m². In addition, increased resorption occurred at 9.3 mg/kg. Colistimethate sodium was not teratogenic in rats at 4.15 or 9.3 mg/kg. These doses are 0.13 and 0.30 times the maximum daily human dose based on mg/m². There are no adequate and well-controlled studies in pregnant women. Since colistimethate sodium is transferred across the placental barrier in humans, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known whether colistimethate sodium is excreted in human breast milk. However, colistin sulphate is excreted in human breast milk. Therefore, caution should be exercised when colistimethate sodium is administered to nursing women.

Geriatric Use

Clinical studies of colistimethate sodium did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Pediatric Use

In clinical studies, colistimethate sodium was administered to the pediatric population (neonates, infants, children and adolescents). Although adverse reactions appear to be similar in the adult and pediatric populations, subjective symptoms of toxicity may not be reported by pediatric patients. Close clinical monitoring of pediatric patients is recommended.

Information for Patients

Patients should be counseled that antibacterial drugs including Colistimethate for Injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Colistimethate for Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Colistimethate for Injection or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

ADVERSE REACTIONS

The following adverse reactions have been reported:

Gastrointestinal: gastrointestinal upset

Nervous System: tingling of extremities and tongue, slurred speech, dizziness, vertigo, paresthesia, and seizures.

Integumentary: generalized itching, urticaria and rash

Body as a Whole: fever

Laboratory Deviations: increased blood urea nitrogen (BUN), elevated creatinine and decreased creatinine clearance

Respiratory System: respiratory distress and apnea

Renal System: nephrotoxicity and decreased urine output

For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or <http://www.fda.gov/medwatch/>.

OVERDOSAGE

Overdosage with colistimethate sodium can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death. Overdosage with the drug can also cause acute renal failure, manifested as decreased urine output and increases in serum concentrations of BUN and creatinine.

As in any case of overdose, colistimethate sodium therapy should be discontinued and general supportive measures should be utilized.

It is unknown whether colistimethate sodium can be removed by hemodialysis or peritoneal dialysis in overdose cases.

DOSAGE AND ADMINISTRATION

Important: Colistimethate for Injection is supplied in vials containing colistimethate sodium equivalent to 150 mg colistin base activity per vial.

Reconstitution: The **150 mg** vial should be reconstituted with **2 mL** Sterile Water for Injection USP. The reconstituted solution provides colistimethate sodium at a concentration equivalent to 75 mg/mL colistin base activity.

During reconstitution, swirl **gently** to avoid frothing.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If these conditions are observed, the product should not be used.

Dosage

Adults and pediatric patients—Intravenous or Intramuscular Administration: Colistimethate for Injection should be given in 2 to 4 divided doses at dose levels of 2.5 to 5 mg/kg per day for patients with normal renal function, depending on the severity of the infection.

In obese individuals, dosage should be based on ideal body weight.

The daily dose should be reduced in the presence of renal impairment. Modifications of dosage in the presence of renal impairment are presented in Table 1.

TABLE 1. Suggested Modification of Dosage Schedules of Colistimethate for Injection for Adults with impaired Renal Function.

Renal Function	Degree of Impairment			
	Normal	Mild	Moderate	Considerable
Plasma creatinine, mg/100 mL	0.7-1.2	1.3-1.5	1.6-2.5	2.6-4.0
Urea clearance, % of normal	80-100	40-70	25-40	10-25
Dosage	100-150	75-115	66-150	100-150
Unit dose of Colistimethate for Injection, mg				
Frequency, times/day	4 to 2	2	2 or 1	Every 36 hr
Total daily dose, mg	300	150-230	133-150	100
Approximate daily dose, mg/kg/day	5.0	2.5-3.8	2.5	1.5

Note: The suggested unit dose is 2.5-5 mg/kg; however, the time interval between injections should be increased in the presence of impaired renal function.

INTRAVENOUS ADMINISTRATION

1. Direct Intermittent Administration—Slowly inject one-half of the total daily dose over a period of 3 to 5 minutes every 12 hours.
2. Continuous Infusion—Slowly inject one-half of the total daily dose over 3 to 5 minutes.

Add the remaining half of the total daily dose of Colistimethate for Injection to one of the following:

0.9% NaCl

5% dextrose in 0.9% NaCl

5% dextrose in water

5% dextrose in 0.45% NaCl

5% dextrose in 0.225% NaCl

Lactated Ringer's solution

10% invert sugar solution

There is not sufficient data to recommend the usage of Colistimethate for Injection with other drugs or other than the above listed infusion solutions.

Administer the second half of the total daily dose by slow intravenous infusion, starting 1 to 2 hours after the initial dose, over the next 22 to 23 hours. In the presence of impaired renal function, reduce the infusion rate depending on the degree of renal impairment.

The choice of intravenous solution and the volume to be employed are dictated by the requirements of fluid and electrolyte management.

Any final intravenous infusion solution containing colistimethate sodium should be freshly prepared and used for no longer than 24 hours.

INTRAMUSCULAR ADMINISTRATION

1. For Intramuscular Injection, administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh).

Store reconstituted solution for intramuscular injection in a refrigerator 2° to 8°C (36° to 46°F) or between 20° to 25°C (68° to 77°F) and use within 7 days.

HOW SUPPLIED

Rx only

Colistimethate for Injection USP is supplied in vials (NDC 39822-0615-1) containing colistimethate sodium (equivalent to 150 mg colistin base per vial) as a white to slightly yellow lyophilized cake and is available as twelve vial per carton (NDC 39822-0615-2).

Storage and Handling

Store between 20° to 25°C (68° to 77°F). Excursions permitted to 15° to 30°C (59° to 86°F). (See USP controlled room temperature).

Store reconstituted solution in refrigerator 2° to 8°C (36° to 46°F) or

between 20° to 25°C (68° to 77°F) and use within 7 days.

Manufactured for:

X-GEN Pharmaceuticals, Inc.

Big Flats, NY 14814

Manufactured in the USA

COLI-PI12-01

Revised September 2017

REFERENCES

1. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement*. CLSI document M100-S18. Wayne, PA: Clinical and Laboratory standards Institute, 2008
2. CLSI. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Seventh Edition*. CLSI document M7-A7. Wayne, PA: Clinical and Laboratory standards Institute, 2006
3. Kroeger, LA, et al. Colistin Methanesulfonate Against Multidrug-Resistant *Acinetobacter baumannii* in an In Vitro Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, Sep 2007; 51(9): 3431-3433
4. Arnold, TM, et al. Polymyxin antibiotics for gram-negative infections. *American Journal of Health-System Pharm*, April 2007; 64: 819-826
5. Ratnam, I, et al. In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit. *Pathology*. 2007; 39(6): 586-588
6. Cunha, BA. New Uses for Older Antibiotics: Nitrofurantoin, Amikacin, Colistin, Polymyxin B, Doxycycline, and Minocycline Revisited. *The Medical Clinics of North America*, 2006; 90: 1089-1107
7. Berlana, D. et al. Use of colistin in the treatment of multiple-drug resistant gram-negative infections. *American Journal of Health-System Pharm*, Jan2005; 62: 39-47
8. Garnacho-Montero, J, et al. Treatment of Multidrug-Resistant *Acinetobacter baumannii* Ventilator-Associated Pneumonia (VAP) with Intravenous colistin: A Comparison with Imipenem-Susceptible VAP. *Clinical Infectious Diseases*, May 2003; 36: 1111-1118
9. Markou, N. et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. *Critical Care*, Oct 2003; 7(5): R78-R83
10. Levin AS, et al. Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug-Resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Clinical Infectious diseases*, 1999; 28: 1008-1011

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 39822-0615-1

Colistimethate for Injection, USP

150 mg Colistin Base Activity

For Intramuscular and Intravenous Use

Rx Only

1 Vial

X-GEN Pharmaceuticals, Inc.

NDC 39822-0615-1

Made in USA

**Colistimethate
for Injection USP**

**Equivalent to
150 mg*colistin**

For Intramuscular
and Intravenous Use

X-GEN
PHARMACEUTICALS INC.

Rx only

***Each vial contains:** Sterile Colistimethate Sodium equivalent to 150 mg Colistin Base. The sodium content is approximately 0.1 mg (0.004 mEq) of sodium per milligram of Colistin.

Usual Dosage: For full prescribing information and directions on reconstitution, see package insert.

Store at 20° to 25°C (68° to 77°F). See USP.

Manufactured for:

X-GEN
PHARMACEUTICALS INC.

Big Flats, NY 14814

CM VL 00



008024

NDC 39822-0615-1
Colistimethate for Injection, USP
150 mg Colistin Base Activity
For Intramuscular and Intravenous Use
Rx Only
Single Vial Carton
X-GEN Pharmaceuticals, Inc.



NDC 39822-0615-2
Colistimethate for Injection, USP
150 mg Colistin Base Activity
For Intramuscular and Intravenous Use
Rx Only
12 Vial Tray Pack
X-GEN Pharmaceuticals, Inc.

NDC 39822-0615-2

12 Vials

Colistimethate for Injection USP

Equivalent to 150 mg* Colistin

FOR INTRAMUSCULAR AND INTRAVENOUS USE

Manufactured for:



Big Flats, NY 14814

Rx only

COLISTIMETHATE

colistimethate injection, powder, lyophilized, for solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:39822-0615
Route of Administration	INTRAMUSCULAR, INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
COLISTIMETHATE SODIUM (UNII: XW0E5YS77G) (COLISTIMETHATE - UNII:DL2R53P963)	COLISTIN	150 mg in 2 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:39822-0615-2	12 in 1 CARTON	01/01/2011	
1	NDC:39822-0615-1	1 in 1 CARTON		
1		2 mL in 1 VIAL; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA064216	01/01/2011	

Labeler - XGen Pharmaceuticals DJB, Inc. (117380305)

